Protalex, Inc. today announced that data from pre-clinical studies of its PRTX-100 compound in development for the treatment of autoimmune and inflammatory diseases, demonstrated efficacy in well-established murine (mouse) models of rheumatoid arthritis. The data from the pre-clincial studies were presented today by Joe J. Dervan, Ph.D., Director of Protein Chemistry and Biopharmaceutical Manufacturing at Protalex, at the Fifth International Conference on Autoimmune Disorders in Sorrento, Italy.
The pre-clincial studies involved administering PRTX-100 into collagen-induced arthritis (CIA) murine models, which mirror many of the disease symptoms of rheumatoid arthritis, including polyarthritis, synovitis and caritage/bone erosions. In the studies, reduction in clinical scores and pathology with PRTX-100 were equivalent to the suppression seen in mice treated with etanercept (Enbrel), an FDA-approved treatment for rheumatoid arthritis. Furthermore, PRTX-100 was able to delay onset and decrease severity of symptoms.
"We are encouraged by the results of the study, particularly because PRTX-100 demonstrated efficacy in the gold-standard model for evaluating rheumatoid arthritis therapies," said Steven H. Kane, President and Chief Executive Officer of Protalex. "The study reinforces our belief in the potential of PRTX-100."
PRTX-100 is a highly-purified form of Staphylococcal Protein A. PRTX-100 binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases, enabling the compound to modulate the function of these cells and restore the balance of the immune system.
Subscribe via RSS
